Inhibrx Biosciences Inc. announced it will host a live webcast presentation on October 23, 2025, at 1:30 p.m. Pacific Time to present topline results from the registrational ChonDRAgon study. The study investigates ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. The company will also provide updates on ongoing expansion trials evaluating ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan and temozolomide in refractory Ewing sarcoma. The results have not yet been presented and will be shared during the upcoming webcast.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA04721) on October 22, 2025, and is solely responsible for the information contained therein.